A perspective on HPK1 as a novel immuno-oncology drug target.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 32896273.
- Also identified by DOI 10.7554/eLife.55122 and PMC identifier 7478889.
- Licence recorded as CC BY.
- The licence permits redistribution, so the abstract is shown in full and the full text is available from the publisher.
Abstract
In this perspective review, the role Hematopoietic Progenitor Kinase 1 (HPK1) in tumor immunity will be reviewed, with special emphasis on how T cells are negatively-regulated at different junctures of cancer-immunity cycle by this regulatory kinase. The review will highlight the strengths and weaknesses of HPK1 as a candidate target for novel immuno-oncology (IO) drug development that is centered on the use of small molecule kinase inhibitor to modulate the immune response against cancer. Such a therapeutic approach, if proven successful, could supplement the cancer cell-centric standard of care therapies in order to fully meet the therapeutic needs of cancer patients.
Medical subject headings
- Antineoplastic Agents
- Immunity
- Neoplasms
- Protein Serine-Threonine Kinases